Real world study assessing safety and efficacy of Vorasidenib
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Vorasidenib (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2024 New trial record
- 24 Nov 2024 According to Servier media release, a real-world study is underway simultaneously in BoaoLecheng to assess the safety and efficacy of Vorasidenib in the Chinese patients.